AUA2024: AUA Advanced Prostate Cancer Guidelines

CME Available: https://auau.auanet.org/node/41027

At the conclusion of this activity, participants will be able to:
1. Identify appropriate use of genetic testing and genetic counseling.
2. Identify appropriate use of somatic testing and treatments related to specific genetic alterations.
3. Identify appropriate combination therapy with androgen deprivation therapy plus novel androgen access therapies and chemotherapy. Early treatment intensification will be discussed in metastatic hormone-sensitive prostate cancer.
4. Identify the treatments for nonmetastatic CRPC and oncologic outcomes based on AUA/SUO (Society of Urologic Oncology) Guidelines.
5. Cancel patients on available treatment options for CRPC as well as combination therapy and sequencing based on AUA/SUO Guidelines.

ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from:
Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.